Matchmaking & Partnering

The corporate investor arms of Eli Lilly, Sanofi and Pfizer have participated in billions worth of venture capital rounds, but GV is the industry's biggest spender. Lilly USA is the most prolific dealmaker in life sciences VC, participating in 38 total deals since January 1, but the total worth of these transactions was lower than GV's spend, at a cumulative $2.5 billion. Other major corporate VC actors in the pharma industry include Sanofi Ventures, which participated in 30 deals for a cumulative $3.7 billion, and Pfizer Ventures, which notched 18 deals for $1.3 billion. Fundraisings have slowed in the third quarter but the bank predicts the trend will push 2026 to $33 billion, topping last year's $30.5 billion.

Why it matters: America's dysfunctional elder care system isn't ready for a flood of aging baby boomers with chronic illnesses and mobility issues, and the cost of hiring help to care for an elderly or sick person at home has been growing much faster than inflation. While that kind of change would be a huge political lift in a divided government, the growing public acceptance of single-payer health care could make it a prominent part of Democrats' health agenda in the next Congress. What they're saying: Senate Democrats are determined to deliver an equitable and affordable home care guarantee for all Americans in need, improve the quality of long-term care across the board, and make sure there are workers in good jobs to meet that need," said Senate Finance ranking Democrat Ron Wyden of Oregon. Americans may have more appetite for a long-term care system if it's framed as social insurance and not a new welfare program or open-ended tax-financed benefit, according to a new Brookings Institution study that notes public skepticism about the likelihood of a fix."

Europe's universities and public research organisations are at the forefront of scientific discovery, but breakthroughs must move from the lab to the market if they are to create jobs, growth and strategic autonomy, said EPO President António Campinos. The study presented today identifies six priorities to help Europe turn research excellence into market success." European TTOs vary widely in size, maturity and activity Of the 809 TTOs analysed, 90.5% were small or mid-scale, while 9.5% were large-scale offices. Public research is increasingly important in strategic technologies European patent applications involving a university, public research organisation or research hospital have more than doubled in the past two decades, from around 3 200 in 2006 to almost 8 000 in 2025. New tools to explore Europe's public research landscape Alongside the report, the EPO is launching a Data Desk dashboard on European public research, enabling users to explore patenting activity by country, institution and technology."

EQT och Qiagen meddelade förra veckan att de har nått en överenskommelse om ett uppköp av det nederländska bolaget. Qiagen utvecklar bland annat produkter för att isolera och analysera DNA och RNA från biologiska prover. Qiagen har sitt huvudkontor i Venlo i Nederländerna och är en av de större internationella aktörerna inom molekylärdiagnostik och laboratorieteknik. – Vi har följt Qiagen noga under många år och länge imponerats av bolagets anseende och den positiva betydelsen av dess produkter och tjänster, säger Matteo Thun-Hohenstein, partner på EQT, i ett pressmeddelande.

58 Milliarden Euro haben die gesetzlichen Krankenkassen 2025 für verschreibungspflichtige Medikamente gezahlt – Rekord! Die Ausgaben steigen seit Jahren. Allein zwischen 2021 und 2025 haben sich sie um knapp 25 Prozent erhöht. Ein wesentlicher Grund: Rezeptpflichtige Medikamente werden im Schnitt immer teurer. Aber warum? WISO-Reporterin Kaja Adchayan findet in dieser Folge „DEALS heraus, wie das Geschäft mit Medikamenten funktioniert. Wie kann es sein, dass Medikamente inzwischen 100.000 Euro pro Packung kosten können? Wer legt diese Preise fest?"